S275
Clinical - Breast
ESTRO 2026
Keywords: toxicity, synthetic data, prediction
significant association (p = 0.462). In the multivariate analysis, several factors were independently associated with insomnia. Somatic disturbances (p < 0.001; OR = 3.00), cognitive disturbances (p = 0.032; OR = 2.35), and poor sleep habits (p = 0.029; OR = 2.01) emerged as significant predictors, increasing the likelihood of insomnia by approximately three-fold, 2.3-fold, and two-fold, respectively. Stress showed a trend toward association without reaching statistical significance (p = 0.058; OR = 2.39), while natural aging did not have a significant influence (p = 0.793).The main reported consequences of insomnia were fatigue (60%), impaired daily functioning (54%), and mood disturbances (67%). Conclusion: Sleep disorders are frequent among patients followed for breast cancer, affecting nearly half of the study population. These findings highlight the need for systematic screening and early management of insomnia to improve patients’ quality of life
Digital Poster 2411
Insomnia as a marker of psychological distress in patients with breast cancer : A cross-sectional study of 100 cases Boubaker Abir 1 , Ben Hassine Samia 1 , Tarhouni Farah 1 , Jaffel Hager 1 , Abid Wiem 1 , Mahjoub Najet 2 1 Radiotherapy Oncology Department, Jendouba Oncology Center, jendouba, Tunisia. 2 Oncology Department, Jendouba Oncology Center, jendouba, Tunisia Purpose/Objective: Insomnia is a common but often underrecognized symptom among cancer patients. The diagnosis announcement, therapeutic procedures, and psychological distress are major factors contributing to poor sleep quality. These disturbances may persist during and after treatment, significantly affecting patients’ quality of life.This study aimed to assess the prevalence of insomnia, its contributing factors, and its impact on daily functioning among patients followed for non-metastatic breast cancer. Material/Methods: We conducted a cross-sectional descriptive observational study at Jendouba Oncology Center. One hundred non-metastatic breast cancer patients were included at different stages of their curative treatment. Clinical, histological, and therapeutic data were collected from medical records. Sleep quality was assessed using a standardized questionnaire — the Insomnia Severity Index (ISI) — administered during follow-up consultations. Results: The median age was 52 years.The predominant histological type was infiltrating ductal carcinoma. Immunohistochemical analysis showed a predominance of the luminal B subtype (39%). At the time of questionnaire administration, most patients were receiving hormone therapy; 6 were undergoing neoadjuvant chemotherapy, 7 adjuvant chemotherapy, and 32 were receiving radiotherapy.Based on the Insomnia Severity Index (ISI), 33 patients reported no insomnia, 42 had subclinical insomnia, 24 moderate insomnia, and 1 severe insomnia. Overall, 46% of the patients were above the pathological threshold (ISI > 10). The most frequently reported contributing factors were cognitive disturbances and stress (70%), followed by somatic symptoms (66%). In the univariate analysis, cognitive disturbances (p < 0.001), somatic disturbances (p < 0.001), and stress (p < 0.001) were significantly associated with insomnia severity, whereas the natural aging process showed no
throughout the therapeutic pathway. Keywords: breast cancer, insomnia,
Digital Poster 2414
Impact of Cancer Treatments on Sexual Health in Young Breast Cancer Survivors: Results from a Tunisian Cohort Jaffel Hager 1 , Boubaker Abir 1 , Bouabidi Oumaima 1 , Ben Hassine Samia 1 , Tarhouni Farah 1 , Abid Wiem 1 , Mahjoub Najet 2 1 Radiotherapy Oncology Department, Jendouba Oncology Center, Jendouba, Tunisia. 2 Oncology Department, Jendouba Oncology Center, Jendouba, Tunisia Purpose/Objective: Sexual health is a critically overlooked aspect of quality of life in young breast cancer (BC) survivors. This study aimed to assess sexual dysfunction (SD) in young women treated for BC and to identify specific treatment-related factors associated with its decline. Material/Methods: We conducted a cross-sectional study involving 62 women aged under 50 years treated for BC at the Jendouba Oncology Center. Participants completed the EORTC QLQ SH22 questionnaire assessing treatment history, sexual satisfaction, vaginal symptoms (e.g., dryness, decreased sensitivity), psychological distress (depressive symptoms, sleep disorders, reduced libido), relational difficulties, and their perception of treatment-related impact. Results: The median age was 43 years (34-50). All patients received radiotherapy, 75.8% (n=47) received chemotherapy, and 75.8% (n=47) received hormone
Made with FlippingBook - Share PDF online